<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619266</url>
  </required_header>
  <id_info>
    <org_study_id>2014YLC32</org_study_id>
    <secondary_id>2015CB554504</secondary_id>
    <nct_id>NCT02619266</nct_id>
  </id_info>
  <brief_title>The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers</brief_title>
  <official_title>The Traditional Chinese Medicine Department of Xin Qiao Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trail will be carried out to evaluated the effect and safety of acupuncture for the
      anorexia in patients with gastrointestinal tract and lung cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acupuncture used for anorexia related to cancer, but there were lack of powerful evidence.
      The 160 eligibilities will be randomly divided into 3 groups(Acupuncture and Placebo group,
      Megestrol acetate and Sham Acupuncture group, Placebo and Sham Acupuncture group).The effect
      will be investigated baseline, the 2,5,8 and 15days. The safety issue will be recorded every
      section during the acupuncture.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appetite Visual Analog Scale</measure>
    <time_frame>Baseline, the days 8 and 15.</time_frame>
    <description>The assessment will be done thirty minutes before meals. The participators should record the score of their appetite (0 to 100 mm) the higher scores reflect better symptom control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Council of Nutrition appetite questionnaire (CNAQ)</measure>
    <time_frame>Baseline, the days 8 and 15.</time_frame>
    <description>Ask the subjects to complete the questionnaire by circling the correct answers and then tally the results based upon the following numerical scale: a =1, b = 2, c = 3, d = 4, e = 5. The sum of the scores for the individual items constitutes the CNAQ score. CNAQ score ≤28 indicates significant risk of at least 5% weight loss within six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caloric intake</measure>
    <time_frame>Baseline, the days 8 and 15.</time_frame>
    <description>The caloric intake will be assessed by the dietician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Anorexia/Cachexia Therapy</measure>
    <time_frame>Baseline, the days 8 and 15.</time_frame>
    <description>Functional Assessment of Anorexia/Cachexia Therapy was designed to measure general aspects of quality of life (QOL) as well as specific anorexia/cachexia-related concerns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Baseline, the days 8 and 15.</time_frame>
    <description>weight was determined in kilograms. Triceps skinfold (mm), arm circumference(cm), and calf circumference (cm) were determined</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Edmonton Symptom Assessment Scale</measure>
    <time_frame>Baseline, the days 8 and 15.</time_frame>
    <description>Edmonton Symptom Assessment Scale is a nine-item patient-rated symptom visual analogue scale developed for use in assessing the symptoms of patients receiving palliative care.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Questionnaire of Acupuncture—related Events(QAE)</measure>
    <time_frame>Baseline and the days 7</time_frame>
    <description>The side effects and their detail will be record during and after the acupuncture.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Anorexia</condition>
  <condition>Cancer Cachexia</condition>
  <arm_group>
    <arm_group_label>Acupuncture+Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Megestrol Acetate+Sham acupuncture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Sham acupuncture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.</description>
    <arm_group_label>Acupuncture+Placebo</arm_group_label>
    <other_name>Real acupuncture</other_name>
    <other_name>True acupuncture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Acupuncture</intervention_name>
    <description>Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.</description>
    <arm_group_label>Megestrol Acetate+Sham acupuncture</arm_group_label>
    <arm_group_label>Placebo+Sham acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol Acetate</intervention_name>
    <description>Megestrol Acetate 160mg tablet</description>
    <arm_group_label>Megestrol Acetate+Sham acupuncture</arm_group_label>
    <other_name>Positive Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(Megestrol Acetate)</intervention_name>
    <description>Starch pill manufactured to mimic Megestrol Acetate 160mg tablet</description>
    <arm_group_label>Acupuncture+Placebo</arm_group_label>
    <arm_group_label>Placebo+Sham acupuncture</arm_group_label>
    <other_name>Placebo Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed gastrointestinal tand lung cancers;

          2. Age ≥18 years;

          3. Appetite score≤ 6 (0= worst appetite), and the symptom lasted 2 weeks at lest at
             screening;

          4. Had a history of weight loss ≥5% within 6 moths;

          5. Maintained oral intake;

          6. Signed the informed consent.

        Exclusion Criteria:

          1. Patients with dementia, delirium, intestinal obstruction, pregnancy or lactation;

          2. Had uncontrolled symptoms that could impact appetite or caloric intake such as nausea,
             pain, or depression(The score of the symptoms≤ 3, 0= worst) ;

          3. Patients with untreated vitamin B12 deficiency or endocrine abnormalities(thyroid
             dysfunction and hypoadrenalism);

          4. Patients on melatonin supplements or medications with potential appetite-stimulating
             activity(Chinese herb,thalidomide)

          5. Less than one week before the screening or there will be a surgery ,radiotherapy and
             chemotherapy the acupuncture;

          6. Lifetime expected less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Tang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chengdu University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaoting Zhao, MD</last_name>
    <role>Study Director</role>
    <affiliation>XinQiao Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haiou Luo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>XinQiao Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zihui Xu, PhD</last_name>
    <phone>86—023—68755615</phone>
    <email>zihuixu@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Cui, MD</last_name>
    <phone>86-023-68774249</phone>
    <email>cuiyendian@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chongqing TCM Hospital</name>
      <address>
        <city>Jiangbei</city>
        <state>Chongqing</state>
        <zip>402760</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Li, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jing Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XinQiao Hosiptal</name>
      <address>
        <city>Shapingba</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zihui Xu, PhD</last_name>
      <email>zihuixu@yeah.net</email>
    </contact>
    <investigator>
      <last_name>Haiou Luo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Donghua Hosiptal</name>
      <address>
        <city>Shapingba</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Li, MD</last_name>
      <phone>86+15023101890</phone>
    </contact>
    <investigator>
      <last_name>Dong Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Yuzhong</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jinglu Shan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/show/NCT02148159</url>
    <description>Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer</description>
  </link>
  <reference>
    <citation>Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013 Apr 1;31(10):1271-6. doi: 10.1200/JCO.2012.43.6766. Epub 2013 Feb 25.</citation>
    <PMID>23439759</PMID>
  </reference>
  <reference>
    <citation>Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, Baracos V. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003 Jan 1;21(1):129-34.</citation>
    <PMID>12506181</PMID>
  </reference>
  <reference>
    <citation>Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990 Sep 15;66(6):1279-82.</citation>
    <PMID>2205358</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Chaoting Zhao</investigator_full_name>
    <investigator_title>Vice Director, Clinical Reseach</investigator_title>
  </responsible_party>
  <keyword>Cancer Anorexia Cachexia Syndrome</keyword>
  <keyword>Acupuncture</keyword>
  <keyword>Megestrol acetate</keyword>
  <keyword>Poor Appetite</keyword>
  <keyword>Anorexia</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

